Gallopamil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Gallopamil
Accession Number
DB12923
Type
Small Molecule
Groups
Investigational
Description

Gallopamil has been used in trials studying the treatment of Asthma.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Gallopamil HydrochlorideVT4VR32A0T16662-46-7OKCRIUNHEQSXFD-UHFFFAOYSA-N
Categories
UNII
39WPC8JHR8
CAS number
16662-47-8
Weight
Average: 484.637
Monoisotopic: 484.293722396
Chemical Formula
C28H40N2O5
InChI Key
XQLWNAFCTODIRK-UHFFFAOYSA-N
InChI
InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
IUPAC Name
5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)-2-(3,4,5-trimethoxyphenyl)pentanenitrile
SMILES
COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C#N)C(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Gallopamil.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Gallopamil.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Gallopamil.Approved, Investigational
AmobarbitalThe metabolism of Gallopamil can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Gallopamil.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Gallopamil.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Gallopamil.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Gallopamil.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Gallopamil is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Gallopamil.Experimental
BarbexacloneThe metabolism of Gallopamil can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Gallopamil can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Gallopamil.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Gallopamil.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Gallopamil.Experimental
BucindololBucindolol may increase the hypotensive activities of Gallopamil.Investigational
BunazosinBunazosin may increase the hypotensive activities of Gallopamil.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Gallopamil.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Gallopamil.Approved
Calcium AcetateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Gallopamil.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Gallopamil.Experimental
CarbomycinThe metabolism of Gallopamil can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Gallopamil.Approved, Investigational
CaseinThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Gallopamil.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Gallopamil.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Gallopamil.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Gallopamil.Approved, Investigational
CimetidineThe serum concentration of Gallopamil can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Gallopamil can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gallopamil.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Gallopamil.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gallopamil.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallopamil.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Gallopamil.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Gallopamil.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Gallopamil.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Gallopamil.Approved
EfavirenzThe serum concentration of Gallopamil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Gallopamil.Approved
ErythromycinThe metabolism of Gallopamil can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Gallopamil.Experimental
FluconazoleThe serum concentration of Gallopamil can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Gallopamil.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Gallopamil.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Gallopamil.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Gallopamil.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Gallopamil.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Gallopamil.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Gallopamil.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Gallopamil.Approved, Investigational
HexobarbitalThe metabolism of Gallopamil can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Gallopamil.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Gallopamil.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Gallopamil.Approved, Investigational
JosamycinThe metabolism of Gallopamil can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Gallopamil.Approved, Investigational
KitasamycinThe metabolism of Gallopamil can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Gallopamil.Approved
LovastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Gallopamil.Experimental
MethohexitalThe metabolism of Gallopamil can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Gallopamil can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Gallopamil.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Gallopamil.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Gallopamil.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Gallopamil.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Gallopamil.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Gallopamil.Experimental
NafcillinThe metabolism of Gallopamil can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Gallopamil.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Gallopamil.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Gallopamil.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Gallopamil.Investigational
NitroprussideGallopamil may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Gallopamil.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Gallopamil.Approved, Vet Approved
OleandomycinThe metabolism of Gallopamil can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Gallopamil.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Gallopamil.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Gallopamil.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Gallopamil.Approved
PentobarbitalThe metabolism of Gallopamil can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Gallopamil can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Gallopamil.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Gallopamil.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Gallopamil.Approved
PrimidoneThe metabolism of Gallopamil can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Gallopamil.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Gallopamil.Experimental
RifabutinThe serum concentration of Gallopamil can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Gallopamil can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Gallopamil can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Gallopamil can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Gallopamil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Gallopamil.Approved, Vet Approved
SecobarbitalThe metabolism of Gallopamil can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Gallopamil.Approved
SilodosinSilodosin may increase the hypotensive activities of Gallopamil.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Gallopamil is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Gallopamil.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Gallopamil.Approved, Investigational
SolithromycinThe metabolism of Gallopamil can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Gallopamil.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Gallopamil.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Gallopamil.Approved
TelithromycinThe metabolism of Gallopamil can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Gallopamil.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Gallopamil.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Gallopamil.Approved
ThiamylalThe metabolism of Gallopamil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Gallopamil can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Gallopamil.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Gallopamil.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Gallopamil.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Gallopamil.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Gallopamil.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Gallopamil.Approved, Investigational
TylosinThe metabolism of Gallopamil can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Gallopamil is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Gallopamil.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Gallopamil.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C13764
PubChem Compound
1234
PubChem Substance
347829068
ChemSpider
1197
BindingDB
82061
ChEBI
34772
ChEMBL
CHEMBL51149
ATC Codes
C08DA02 — Gallopamil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00548 mg/mLALOGPS
logP4.42ALOGPS
logP4.89ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area73.18 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity139.11 m3·mol-1ChemAxon
Polarizability55.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylbutylamines
Direct Parent
Phenylbutylamines
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenethylamines / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Nitriles / Organopnictogen compounds
show 1 more
Substituents
Phenylbutylamine / Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Alkyl aryl ether
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organic amino compound, benzenes (CHEBI:34772)

Drug created on October 20, 2016 19:18 / Updated on December 01, 2017 17:37